Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Express Scripts
Chinese Patent Office
US Department of Justice
Queensland Health
Farmers Insurance
Harvard Business School
Mallinckrodt
Citi

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,743,798

« Back to Dashboard

Which drugs does patent 6,743,798 protect, and when does it expire?

Patent 6,743,798 protects ADEMPAS and is included in one NDA.

This patent has thirty-four patent family members in thirty countries.
Summary for Patent: 6,743,798
Title: Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
Abstract:The present invention relates to novel substituted pyrazole derivatives of the general formula (I) ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and A are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.
Inventor(s): Straub; Alexander (Wuppertal, DE), Feurer; Achim (Odenthal, DE), Alonso-Alija; Cristina (Haan, DE), Stasch; Johannes-Peter (Solingen, DE), Perzborn; Elisabeth (Wuppertal, DE), Hutter; Joachim (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Stahl; Elke (Bergisch Gladbach, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/744,830
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 6,743,798

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-001 Oct 8, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-002 Oct 8, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-003 Oct 8, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Bayer Hlthcare ADEMPAS riociguat TABLET;ORAL 204819-004 Oct 8, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,743,798

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany198 34 044Jul 29, 1998
PCT Information
PCT FiledJuly 16, 1999PCT Application Number:PCT/EP99/05074
PCT Publication Date:February 10, 2000PCT Publication Number: WO00/06569

International Patents Family Members for US Patent 6,743,798

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016736 ➤ Try a Free Trial
Austria 313543 ➤ Try a Free Trial
Australia 5284099 ➤ Try a Free Trial
Australia 751316 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Argus Health
Queensland Health
Deloitte
Harvard Business School
Cerilliant
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.